Analytical procedure development and proposed established conditions: A case study of a mass spectrometry based NDSRI analytical procedure.

NDSRI (Nitrosamine drug substance-related impurity analytical target profile established conditions knowledge management mass spectrometry risk assessment

Journal

Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R

Informations de publication

Date de publication:
05 Aug 2024
Historique:
received: 28 05 2024
revised: 26 07 2024
accepted: 27 07 2024
medline: 8 8 2024
pubmed: 8 8 2024
entrez: 7 8 2024
Statut: aheadofprint

Résumé

With the finalization of the ICH Q14 Analytical Procedure Development guideline, how to apply enhanced approaches (such as analytical quality by design (AQbD)) to develop an analytical procedure, and to propose Established Conditions (ECs) and corresponding reporting categories, is increasingly being discussed. To gain practical experience in applying an enhanced approach for method development and identifying ECs, we developed, validated, and implemented an analytical procedure for a nitrosamine drug substance-related impurity (NDSRI). Here, as an example of the application of Q12 Lifecycle Management guideline principles in regards to analytical procedures, we briefly elaborate how: 1) the principles documented in the ICH Q14 guideline for analytical procedure development were applied, with the focus on identifying an Analytical Target Profile (ATP), knowledge management and risk assessment; 2) analytical procedure robustness according to the recommendations in ICH Q2(R2) Validation of Analytical Procedure guideline and Q14, were evaluated; and 3) mass spectrometry ECs and associated proposed reporting categories were proposed.

Identifiants

pubmed: 39111548
pii: S0022-3549(24)00266-1
doi: 10.1016/j.xphs.2024.07.022
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Jinhui Zhang (J)

Division of Product Quality Research, Office of Testing and Research, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, 10903 New Hampshire Avenue, Silver Spring, MD 20993, United States. Electronic address: Jinhui.Zhang@fda.hhs.gov.

Ramesh Raghavachari (R)

Division of Post-Marketing Activities I, Office of Lifecycle Drug Products, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, 10903 New Hampshire Avenue, Silver Spring, MD 20993, United States.

Douglas C Kirkpatrick (DC)

Office of Testing and Research, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, 10903 New Hampshire Avenue, Silver Spring, MD 20993, United States.

David A Keire (DA)

Office of Testing and Research, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, 10903 New Hampshire Avenue, Silver Spring, MD 20993, United States.

Xiaoming Xu (X)

Division of Product Quality Research, Office of Testing and Research, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, 10903 New Hampshire Avenue, Silver Spring, MD 20993, United States.

Patrick J Faustino (PJ)

Division of Product Quality Research, Office of Testing and Research, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, 10903 New Hampshire Avenue, Silver Spring, MD 20993, United States.

Classifications MeSH